Treatment of breast cancer with companion diagnostic
AssigneeThe Regents of the University of California
InventorsMadhuri Wadehra, Jonathan Braun
Life of this patent
Estimating the term…
Abstract
Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the BRCA1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (Her-2/neu), which accounts for approximately half of all breast cancer deaths. Provided herein are compositions and methods for treating breast cancer, including the triple negative subtype.
Claims24
A method of treating a patient for breast cancer, wherein the breast cancer comprises a triple negative breast cancer tumor, the method comprising administering to the patient an effective amount of an antibody wherein the antibody specifically binds to an epitope in the second extracellular loop of EMP2, wherein the epitope comprises the amino acid sequence DIHDKNAKFYPVTREGSYG.
Dependencies are inferred from the claim text.